Synergy Pharmaceuticals

Synergy Pharmaceuticals is a joint venture (JV) with the State Pharmaceutical Corporation (SPC) which aims to become the biggest manufacturer of Pharmaceuticals in the whole South Asia region. The facility is being constructed in the BOI industrial zone, Bingiriya, according to strict standards and international quality considerations with the consultation of Spectrum Consultants, India. The facility features state of the art equipment and machinery from the Rolls Royce of pharmaceutical equipment manufacturers, Glatt Integrated Process Solutions GmbH, Germany. Apart from manufacturing, Synergy R&D Labs aims to become South Asia’s biggest research and development laboratory for all things pharmaceutical.

The project is under construction in 15 acres of prime real estate in the industrial zone and will start manufacturing in Q1, 2022. Project implementation is divided into 3 phases, with each phase starting manufacturing in full capacity before the implementation of the next.

  1. Phase 1: All vital medicine necessary for Sri Lanka of which Sri Lanka has heavy dependency on imports. These include heart medication, diabetitc medication, endocrine (hormonal) medication, contraceptives etc. in the form of capsules and tablets.
  2. Phase 2: This phase will focus on intravenous medication and injectables of vital importance to Sri Lanka. Oncological medication (cancer, tumor and chemo-therepy related), saline, dextrose etc. are those in the pipeline.
  3. Phase 3: Our most exciting venture as we have saved the best for last. Once this phase is unveiled it will make us and by extension, Sri Lanka the dominator in the production and manufacture of this critical commodity.

Our target is to manufacture over 5 billion tablets in the first year with rapid increases in production annually and cover 25% of ALL the medical needs in all of Sri Lanka within 3 years of operation. We are currently in the process of getting certification of the U.S. Food and Drug Administration (FDA), European Medicines Evaluation Agency (EMA) and World Health Organization (WHO) Geneva with the assistance of the world’s best consulting companies. The factory is under construction within the parameters of a Super Sterile Block to comply with international regulations. Our future export target markets are North America, Europe, Africa and Central Asia.

by Numbers20

+5 Billion

tablets annually


Local target market

R&D Lab

Best in emerging markets